Research and drug development solutions are nearly limitless when genome editing technologies are applied to in vitro testing methods and cell based assays. For example, reporter cell lines may serve as a more high-throughput and sensitive method for CYP induction, nuclear receptors activation, genotoxicity, and neurotoxicity. Patient or disease specific cell lines can be engineered by creating or correcting a mutation found in the patient population, leading to more targeted and specific assay development.
Using the latest gene editing technology, Hera is developing new in vitro models to provide improved predictive power for preclinical pharmaceutical toxicology assessments. Listed below are our available or soon to be released cell lines for hepatotoxicity, neurotoxicity, and transporter assays and our services which included custom cell line engineering and assay development.
- GFP+ SH-SY5Y Cells
- HepG2-CYP Hepatotox Cell Panel
Assays and Services
- Cytotoxicity, hepatotoxicity and neurotoxicity
- Neuronal live cell neurite outgrowth/cell migration assays
Why Reporter Cell Lines?
- The FDA and EPA are looking toward gene activation as new standard readout for toxicity and DDI studies (FDA 2012 Guidance to Industry, and Tox21 Program).
- Increased sensitivity (Harrill et al. Neurotoxicology 2010)
- More relevant data in less time and cost
Unique Neural Cell Lines for Screening and Custom Services
- SH-SY5Y – is a human neuroblastoma cell line widely used in systematic toxicological assays (Forsby et al. Toxicol. In Vitro 2009) and high-throughput screenings (Breier et al. Neurotoxicol Teratol 2010, Loh et al. Cell Death Differ 2008). The SH-SY5Y cell line is also used in the study of CNS disorders, including, neurodegenerative diseases such as Alzheimer’s or Parkinson’s diseases. SH-SY5Y cells can be differentiated into mature neurons at a high efficiency which increases their utility for screening.
- LUHMES – is a conditionally immortalized human dopaminergic neuronal precursor cell-line, useful for studying dopamine related toxicity (Lotharius et al. J Neurosci 2005) and behave similarly to primary cells when treated with neurotoxins (Lopes et al. Brain Res (2010), Schildknecht Toxicol. Appl. Pharmacol 2009). LUHMES cells can be effectively differentiated into neurons with homogenous expression of neuronal markers, neurite outgrowth and electrophysiological properties.
- hNP1™ – developed by our strategic partner ArunA Biomedical, is a human ES cell derived neuroprogenitor which has improved sensitivity to chemical-induced apoptosis over differentiated neurons, for use in a developmental neurotoxicity screening (Druwe et al. Toxicology 2015)